La fin de la médecine à taille unique

L'impression 3D pharmaceutique pourrait faire passer la médecine des doses standard à des traitements adaptés à chaque patient. Selon l'intervention, les doses pourraient être ajustées en fonction de l'âge, de l'état de santé, de la génétique et des besoins thérapeutiques, ce qui pourrait améliorer la sécurité, l'efficacité et l'observance. La conférencière, Dr Georgina Marsh, relie également cette approche à la santé numérique et aux défis du système de santé dans le Suffolk.

• Passer de doses standard à une médecine personnalisée
• Adapter les médicaments à l'âge, aux pathologies et à la génétique
• Regrouper plusieurs médicaments dans un seul comprimé

Pharmaceutical 3D printing has the potential to transform healthcare by replacing the traditional “one-size-fits-all” approach with truly personalised medicine. Instead of standard doses, medicines can be tailored to each patient’s age, health conditions, genetics, and treatment needs, improving safety, effectiveness, and adherence. The technology can also combine multiple medications into a single tablet and work alongside digital healthcare systems to create smarter, more efficient care. For Suffolk, where an ageing population, rural healthcare challenges, and increasing pressure on NHS services are growing concerns, personalised medicine could improve access to treatment, reduce medication-related hospital admissions, and bring care closer to home. This talk explores how innovation can help create a more patient-centred and resilient healthcare system. Dr Georgina Marsh is a UK-registered pharmacist and academic leading the development of the Department of Pharmacy at the University of Suffolk. She holds a PhD from the University of Nottingham and specialises in pharmaceutical 3D printing, researching how engineered surface structures can influence particle adhesion, microbial viability, and drug delivery. Her work explores innovative dosage forms tailored to individual patient needs, with the aim of improving therapeutic outcomes through personalised medicine. Georgina's research combines pharmaceutical science, materials engineering, and emerging technologies to advance patient-centred healthcare. Alongside her academic career, Georgina has worked as a Senior Formulation Scientist at AstraZeneca, an Assistant Professor at the University of Nottingham Malaysia, and a Senior Lecturer at Swansea University. She is passionate about shaping the future of digitally enabled pharmacy through research, innovation, and education. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx